HSJN(002817)2023-04-27 16:00Financial Performance - The company's operating revenue for 2022 was ¥428,318,791.71, representing a 12.75% increase compared to ¥379,891,008.70 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥60,850,372.05, a 6.97% increase from ¥56,887,811.36 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,050,352.05, up 5.69% from ¥48,301,265.66 in the previous year[23] - The total assets at the end of 2022 were ¥1,037,692,058.04, down 1.53% from ¥1,053,820,293.60 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥853,758,112.73, an increase of 5.44% from ¥809,694,572.19 at the end of 2021[23] - The basic earnings per share for 2022 were ¥0.20, a 5.26% increase from ¥0.19 in 2021[23] - The diluted earnings per share for 2022 were also ¥0.20, reflecting the same increase of 5.26% from the previous year[23] - The weighted average return on equity for 2022 was 7.34%, slightly up from 7.25% in 2021[23] Cash Flow - The net cash flow from operating activities was ¥83,016,820.72, a decrease of 3.57% from ¥86,089,406.99 in 2021[23] - Operating cash inflow increased by 10.09% to ¥391,715,445.37, while operating cash outflow rose by 14.45% to ¥308,698,624.65[61] - Net cash flow from operating activities decreased by 3.57% to ¥83,016,820.72[61] - Investment cash inflow surged by 258.65% to ¥545,466,959.68, while investment cash outflow increased by 204.74% to ¥559,132,194.23[61] - Net cash flow from investment activities improved by 56.47% to -¥13,665,234.55[62] - Cash and cash equivalents decreased by 124.69% to -¥25,285,572.34, primarily due to reduced financing cash flow[62] Revenue Breakdown - The company's total revenue for Q1 2022 was approximately CNY 101.31 million, with a peak in Q4 2022 at CNY 127.14 million, indicating a quarterly fluctuation of 25.3%[27] - Net profit attributable to shareholders for Q2 2022 was CNY 17.55 million, while Q4 2022 saw a decline to CNY 12.75 million, reflecting a decrease of 27.5%[27] - The sales of gel capsules accounted for 79.17% of total revenue, with a revenue of ¥339,080,226.02, up 10.88% from ¥305,805,926.12 in 2021[50] - Domestic sales reached ¥397,971,632.29, making up 92.91% of total revenue, while international sales surged by 157.43% to ¥30,347,159.42, representing 7.09% of total revenue[50] Research and Development - Research and development investment amounted to 14.98 million yuan, with 8 patent applications filed, including 3 invention patents[47] - R&D investment rose by 11.47% to ¥14,980,970.94, accounting for 3.50% of operating revenue[59] - The company has initiated several new product development projects, including hydroxypropyl methylcellulose hollow capsules, aiming for annual sales of 4 billion pieces[58] - Research and development expenses rose by 11.47% to ¥14,980,970.94 in 2022, compared to ¥13,439,131.79 in 2021[58] Market Strategy - The pharmaceutical industry is transitioning towards high-quality development, with a focus on product innovation and international expansion as outlined in the "14th Five-Year Plan" for the pharmaceutical industry[33] - The company is enhancing brand promotion in the traditional Chinese medicine sector to adapt to market changes and maintain healthy growth[34] - The company aims to enhance its competitive advantage through continuous investment in technology research and development, aiming to become a leading pharmaceutical technology service platform in China[45] - The company plans to optimize its industrial structure and expand international market presence to overcome development bottlenecks[74] - The company is expanding its human resources management to address the potential mismatch between talent supply and business growth needs[77] Governance and Compliance - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[81] - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making[85] - The company has established a complete and independent financial accounting system, allowing for autonomous financial decision-making[87] - The company has established rules for related party transactions to ensure they follow market principles[89] - The company conducted a self-assessment of its governance structure, finding it compliant with relevant laws and regulations, with no major defects affecting operations[135] Shareholder Information - The company plans to distribute a cash dividend of ¥0.6 per 10 shares, totaling approximately ¥17,945,908.20 based on 299,098,170 shares[4] - The company reported a cash dividend of RMB 17,945,890.20 for the fiscal year, which represents 29.49% of the distributable profit of RMB 411,140,417.21[124] - The total number of shares increased from 213,641,550 to 299,098,170 after a capital reserve conversion, resulting in a 40.00% increase in total shares[180] - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[187] Employee Management - The total number of employees at the end of the reporting period was 681, with 493 in production, 30 in sales, 81 in technical roles, 7 in finance, and 70 in administration[118] - The company implemented a performance-oriented salary system, enhancing employee motivation and retention through various incentive mechanisms[119] - The training completion rate for the year was 100%, with 429 frontline employees trained in SOP and professional knowledge, and 59 new employees receiving pre-job skills training[121] - The company has established a comprehensive training management system, combining internal and external training to enhance employee skills[121] Environmental and Social Responsibility - The company invested in supercritical CO2 heating and cooling systems and catalytic combustion systems, effectively reducing energy consumption and emissions[136] - The company donated 154,500 yuan to social welfare activities, including blood donation and support for disadvantaged employees[137] - The company emphasizes the importance of timely and accurate information disclosure to protect the rights of shareholders and creditors[134] Future Outlook - The company’s future outlook remains positive, with expectations of continued growth in revenue and market share[98] - The company has set a revenue target of 1 billion RMB for the next fiscal year, indicating a growth expectation of 25%[105] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[105] - The company aims to strengthen its competitive position in the industry through potential mergers and acquisitions, although no specific targets were mentioned[98]